Publications
Detailed Information
Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Gyeong-Won | - |
dc.contributor.author | Go, Se-Il | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Kim, Hoon-Gu | - |
dc.contributor.author | Kim, Joo-Hang | - |
dc.contributor.author | An, Ho Jung | - |
dc.contributor.author | Jang, Joung Soon | - |
dc.contributor.author | Kim, Bong-Seog | - |
dc.contributor.author | Hahn, Seokyung | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.date.accessioned | 2021-01-31T08:07:32Z | - |
dc.date.available | 2021-01-31T08:07:32Z | - |
dc.date.created | 2020-05-15 | - |
dc.date.issued | 2020-01 | - |
dc.identifier.citation | Thoracic Cancer, Vol.11 No.1, pp.62-71 | - |
dc.identifier.issn | 1759-7706 | - |
dc.identifier.other | 100121 | - |
dc.identifier.uri | https://hdl.handle.net/10371/171828 | - |
dc.description.abstract | Background Clinical impact of the Geriatric Nutritional Risk Index (GNRI) in patients with extensive-stage disease small cell lung cancer (ED-SCLC) have not previously been reported. Methods This study analyzed 352 patients enrolled in a previous randomized phase III trial comparing the efficacy of irinotecan plus cisplatin with that of etoposide plus cisplatin as the first-line therapy for ED-SCLC. GNRI values were calculated using serum albumin levels and actual and ideal bodyweights. Patients with a GNRI > 98, 92-98, and <92 were grouped into no, low, and moderate/major risk groups, respectively. Results The objective response rates were 63.2%, 52.6%, and 49.2% in the no, low, and moderate/major risk groups, respectively (P = 0.024). The median progression-free survival (PFS) was shorter in patients with a lower GNRI than in those with a higher GNRI (no vs. low vs. moderate/major risk group; 6.5 vs. 5.8 vs. 5.9 months, respectively; P = 0.028). There were significant differences in median overall survival (OS) according to GNRI (no vs. low vs. moderate/major risk group; 13.2 vs. 10.3 vs. 8.4 months, respectively; P < 0.001). Multivariate analysis revealed that being in the moderate/major risk group was an independent poor prognostic factor for PFS (hazard ratio [HR]: 1.300, 95% confidence interval [CI]: 1.012-1.670; P = 0.040) and OS (HR: 1.539; 95% CI: 1.069-2.216; P = 0.020). Conclusions This prospective study shows that a low GNRI value was associated with a poor prognosis, and it supports the relationship between systemic inflammation, nutritional status, and clinical outcomes in patients with ED-SCLC.Key points Significant findings of the study The lower GNRI group had a low response rate to chemotherapy for ED-SCLC. The HRs for PFS and OS were 1.300 and 1.539 in the patients with GNRI < 92. What this study adds Low GNRI is associated with poor prognosis in ED-SCLC. | - |
dc.language | 영어 | - |
dc.publisher | Blackwell Publishing Asia Pty Ltd | - |
dc.title | Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 한서경 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.identifier.doi | 10.1111/1759-7714.13229 | - |
dc.citation.journaltitle | Thoracic Cancer | - |
dc.identifier.wosid | 000505275100010 | - |
dc.identifier.scopusid | 2-s2.0-85074846303 | - |
dc.citation.endpage | 71 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 62 | - |
dc.citation.volume | 11 | - |
dc.identifier.sci | 000505275100010 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Hahn, Seokyung | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | VASCULAR-PERMEABILITY | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | ALBUMIN | - |
dc.subject.keywordPlus | INFLAMMATION | - |
dc.subject.keywordPlus | ETOPOSIDE | - |
dc.subject.keywordPlus | IRINOTECAN | - |
dc.subject.keywordPlus | CACHEXIA | - |
dc.subject.keywordAuthor | Cachexia | - |
dc.subject.keywordAuthor | inflammation | - |
dc.subject.keywordAuthor | nutrition assessment | - |
dc.subject.keywordAuthor | small cell lung carcinoma | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.